石药创新制药股份有限公司控股子公司达雷妥尤单抗注射液获临床试验批件

中金财经2025-12-23

中访网数据石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。该药物为治疗用生物制品3.3类，是原研药兆珂®(达雷妥尤单抗)的生物类似药，靶向CD38，拟用于治疗多发性骨髓瘤成年患者。根据公告，巨石生物已完成相关的药学及非临床研究，结果显示其与原研...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593432493?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 16:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593432493","market":"sh","top_or_hot":-1,"title":"石药创新制药股份有限公司控股子公司达雷妥尤单抗注射液获临床试验批件","media":"中金财经","content":"<div>\n<p>中访网数据  石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。该药物为治疗用生物制品3.3类，是原研药兆珂®(达雷妥尤单抗)的生物类似药，靶向CD38，拟用于治疗多发性骨髓瘤成年患者。根据公告，巨石生物已完成相关的药学及非临床研究，结果显示其与原研...</p>\n\n<a href=\"http://sc.stock.cnfol.com/ggzixun/20251223/31884943.shtml\">网页链接</a>\n\n</div>\n","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药创新制药股份有限公司控股子公司达雷妥尤单抗注射液获临床试验批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药创新制药股份有限公司控股子公司达雷妥尤单抗注射液获临床试验批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 16:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/ggzixun/20251223/31884943.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中访网数据  石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。该药物为治疗用生物制品3.3类，是原研药兆珂®(达雷妥尤单抗)的生物类似药，靶向CD38，拟用于治疗多发性骨髓瘤成年患者。根据公告，巨石生物已完成相关的药学及非临床研究，结果显示其与原研...</p>\n\n<a href=\"http://sc.stock.cnfol.com/ggzixun/20251223/31884943.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226288253.USD","symbol_name":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","start_time":0,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251223/31884943.shtml","article_id":"2593432493","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593432493","pubTimestamp":1766480123,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"中访网数据 石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。公司表示将于近期启动临床试验。此次获得临床试验批准是该药物研发进程中的关键一步，但后续仍需完成临床试验并经国家药监局批准后方可上市销售。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1191":"制药","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","BK1515":"抗疫概念","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","BK1574":"生物医药B类股","LU0140636845.USD":"施罗德大中华区股票A Acc","01093":"石药集团","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","BK1521":"挪威政府全球养老基金持仓","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","01477":"欧康维视生物-B","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC"},"translate_title":"Daratumumab injection, a subsidiary of CSPC Innovation Pharmaceutical Co., Ltd., received clinical trial approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"01477":1.5},"content_text":"中访网数据  石药创新制药股份有限公司于近日发布公告，其控股子公司石药集团巨石生物制药有限公司研发的达雷妥尤单抗注射液，已获得国家药品监督管理局核准签发的《药物临床试验批准通知书》，受理号为CXSL2500876。该药物为治疗用生物制品3.3类，是原研药兆珂®(达雷妥尤单抗)的生物类似药，靶向CD38，拟用于治疗多发性骨髓瘤成年患者。根据公告，巨石生物已完成相关的药学及非临床研究，结果显示其与原研参照药在质量、安全性和有效性方面高度相似，符合开展临床试验的要求。公司表示将于近期启动临床试验。此次获得临床试验批准是该药物研发进程中的关键一步，但后续仍需完成临床试验并经国家药监局批准后方可上市销售。公司亦在公告中提示，药物研发存在周期长、风险高、结果不确定等特点，短期内不会对巨石生物及公司业绩产生重大影响。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593432493","isCrawlerRequest":true}